Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965033 | 0.93 | PARP10 (0.39) | PARP10PARP11ASIC3PARP1MAPK1 | |
| Trifluoroacetic Acid SCHEMBL29964620 | 0.91 | PARP10 (0.42) | PARP10PARP11ASIC3PARP1MAPK1 | |
| Trifluoroacetic Acid SCHEMBL31079143 | 0.88 | PARP10 (0.42) | PARP10PARP11PARP1MAPK1MAPKAPK2 | |
| SCHEMBL29964767 | 0.84 | PARP10 (0.47) | PARP10PARP11ASIC3PARP1MAPK1 | |
| Trifluoroacetic Acid SCHEMBL29964747 | 0.83 | CCNT1 (0.43) | PARP1MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL29965113 | 0.83 | MAPK1 (0.38) | PARP1MAPK1GSK3B | |
| Trifluoroacetic Acid SCHEMBL29964703 | 0.83 | MAPKAPK2 (0.34) | PARP10PARP11PARP1MAPK1MAPKAPK2 | |
| SCHEMBL29965164 | 0.80 | PARP10 (0.47) | PARP10PARP11PARP1MAPK1MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL31079072 | 0.79 | PARP10 (0.40) | PARP10PARP11MAPK1MAPKAPK2GSK3B | |
| Trifluoroacetic Acid SCHEMBL29963900 | 0.79 | PARP10 (0.40) | PARP10PARP11MAPK1MAPKAPK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | PARP10 2072/4885PARP11 1176/4885ASIC3 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.